Misplaced Pages

Ecnoglutide

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.
Experimental drug Pharmaceutical compound
Ecnoglutide
Clinical data
Other namesXW003
Legal status
Legal status
  • Investigational
Identifiers
IUPAC name
  • 18-amino]-3-methylbutanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-4-carboxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-6-amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-6-oxohexyl]amino]-2-oxoethoxy]ethoxy]ethylamino]-2-oxoethoxy]ethoxy]ethylamino]-1-carboxy-4-oxobutyl]amino]-18-oxooctadecanoic acid
CAS Number
PubChem CID
UNII
Chemical and physical data
FormulaC194H304N48O61
Molar mass4284.841 g·mol
3D model (JSmol)
SMILES
  • CC(C)(C(=O)N(CCCCNC(=O)COCCOCCNC(=O)COCCOCCNC(=O)CC(C(=O)O)NC(=O)CCCCCCCCCCCCCCCCC(=O)O)C(=O)N(CC1=CNC2=CC=CC=C21)C(=O)N(CC(C)C)C(=O)N(C(C)C)C(=O)N(CCCNC(=N)N)C(=O)NCC(=O)N(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)(CC3=CC=CC=C3)NC(=O)(CCC(=O)O)NC(=O)(CCCNC(=N)N)NC(=O)(C)NC(=O)(C)NC(=O)(CCC(=O)N)NC(=O)(CCC(=O)O)NC(=O)(CCC(=O)O)NC(=O)(CC(C)C)NC(=O)(CC4=CC=C(C=C4)O)NC(=O)(CO)NC(=O)(CO)NC(=O)(C(C)C)NC(=O)(CC(=O)O)NC(=O)(CO)NC(=O)((C)O)NC(=O)(CC5=CC=CC=C5)NC(=O)((C)O)NC(=O)CNC(=O)(CCC(=O)O)NC(=O)(C(C)C)NC(=O)(CC6=CNC=N6)N
InChI
  • InChI=1S/C194H304N48O61/c1-17-109(12)160(188(295)225-125(51-40-41-73-204-148(254)101-302-83-82-301-80-78-206-149(255)102-303-84-81-300-79-77-205-144(250)68-62-132(191(298)299)218-145(251)55-36-28-26-24-22-20-18-19-21-23-25-27-29-37-56-150(256)257)171(278)231-138(90-117-93-210-122-50-39-38-49-120(117)122)177(284)228-134(86-105(4)5)178(285)239-158(107(8)9)186(293)224-124(53-43-75-208-193(199)200)167(274)211-95-146(252)217-123(52-42-74-207-192(197)198)166(273)213-97-156(268)269)241-179(286)136(87-114-45-32-30-33-46-114)229-174(281)131(66-72-154(264)265)221-170(277)126(54-44-76-209-194(201)202)219-164(271)111(14)215-163(270)110(13)216-169(276)128(61-67-143(196)249)220-172(279)129(64-70-152(260)261)222-173(280)130(65-71-153(262)263)223-175(282)133(85-104(2)3)227-176(283)135(89-116-57-59-119(248)60-58-116)230-182(289)140(98-243)234-184(291)142(100-245)235-187(294)159(108(10)11)240-181(288)139(92-155(266)267)232-183(290)141(99-244)236-190(297)162(113(16)247)242-180(287)137(88-115-47-34-31-35-48-115)233-189(296)161(112(15)246)237-147(253)96-212-168(275)127(63-69-151(258)259)226-185(292)157(106(6)7)238-165(272)121(195)91-118-94-203-103-214-118/h30-35,38-39,45-50,57-60,93-94,103-113,121,123-142,157-162,210,243-248H,17-29,36-37,40-44,51-56,61-92,95-102,195H2,1-16H3,(H2,196,249)(H,203,214)(H,204,254)(H,205,250)(H,206,255)(H,211,274)(H,212,275)(H,213,273)(H,215,270)(H,216,276)(H,217,252)(H,218,251)(H,219,271)(H,220,279)(H,221,277)(H,222,280)(H,223,282)(H,224,293)(H,225,295)(H,226,292)(H,227,283)(H,228,284)(H,229,281)(H,230,289)(H,231,278)(H,232,290)(H,233,296)(H,234,291)(H,235,294)(H,236,297)(H,237,253)(H,238,272)(H,239,285)(H,240,288)(H,241,286)(H,242,287)(H,256,257)(H,258,259)(H,260,261)(H,262,263)(H,264,265)(H,266,267)(H,268,269)(H,298,299)(H4,197,198,207)(H4,199,200,208)(H4,201,202,209)/t109-,110-,111-,112+,113+,121-,123-,124-,125-,126-,127-,128-,129-,130-,131-,132-,133-,134-,135-,136-,137-,138-,139-,140-,141-,142-,157-,158-,159-,160-,161-,162-/m0/s1
  • Key:DJMLKAVQDZZBNC-NYHUXPQOSA-N

Ecnoglutide (XW003) is a GLP-1 agonist being developed for the treatment of obesity and type 2 diabetes. In preclinical trials, "Ecnoglutide showed a favorable potency, pharmacokinetic, and tolerability profile, as well as a simplified manufacturing process" compared to other GLP-1 agonists.

References

  1. Wang, Guang; Hu, Wei; Qin, Hong H.; Zheng, Qing; Ning, Jing; Mengying, Guo; Bu, Yue; Jones, Catherine; Fenaux, Martijn; Xu, Susan; Junaidi, Mohammed K. (20 June 2023). "756-P: A Phase 1c Evaluation of a Novel GLP-1 Analog Ecnoglutide (XW003) for Weight Loss in Adults with Overweight and Obesity". Diabetes. 72 (Supplement_1). doi:10.2337/db23-756-P. S2CID 259383725.
  2. Guo, Wanjun; Xu, Zheng; Zou, Haixia; Li, Feng; Li, Yao; Feng, Jing; Zhu, Zhiyi; Zheng, Qing; Zhu, Rui; Wang, Bin; Li, Yan; Hao, Sujuan; Qin, Hong; Jones, Catherine L.; Adegbite, Eric; Telusca, Libnir; Fenaux, Martijn; Zhong, Weidong; Junaidi, Mohammed K.; Xu, Susan; Pan, Hai (September 2023). "Discovery of ecnoglutide – A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog". Molecular Metabolism. 75: 101762. doi:10.1016/j.molmet.2023.101762. PMC 10339203. PMID 37364710.
  3. Zhu, Dalong; Qin, Hong H.; Zheng, Qing; Ning, Jing; Zhu, Zhiyi; Mengying, Guo; Bu, Yue; Jones, Catherine; Fenaux, Martijn; Xu, Susan; Junaidi, Mohammed K. (20 June 2023). "755-P: A Phase 2 Evaluation of a Novel GLP-1 Analog Ecnoglutide (XW003) for Glycemic Control in Adults with Type 2 Diabetes". Diabetes. 72 (Supplement_1). doi:10.2337/db23-755-P. S2CID 259446339.
  4. Guo, Wanjun; Xu, Zheng; Zou, Haixia; Li, Feng; Li, Yao; Feng, Jing; Zhu, Zhiyi; Zheng, Qing; Zhu, Rui; Wang, Bin; Li, Yan; Hao, Sujuan; Qin, Hong; Jones, Catherine L.; Adegbite, Eric; Telusca, Libnir; Fenaux, Martijn; Zhong, Weidong; Junaidi, Mohammed K.; Xu, Susan; Pan, Hai (September 2023). "Discovery of ecnoglutide - A novel, long-acting, cAMP-biased glucagon-like peptide-1 (GLP-1) analog". Molecular Metabolism. 75: 101762. doi:10.1016/j.molmet.2023.101762. ISSN 2212-8778. PMC 10339203. PMID 37364710.
Stub icon

This medical article is a stub. You can help Misplaced Pages by expanding it.

Categories: